|
Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Submits US Food & Drug Administration orphan drug designation application for the NXP002 programme in idiopathic pulmonary fibrosis. If the orphan drug designation is granted, Nuformix may be eligible for some benefits, like tax credits for clinical trials or qualified clinical testing costs. Executive Director Dan Gooding says: ‘We are very pleased to have submitted the FDA ODD application following confirmation that Orphan Drug Designation has been granted for our NXP002 programme in IPF in the EU by the EMA. Whilst we await the FDA’s response we continue discussions with potential future licensing partners and will provide further updates in due course as appropriate.’ Current stock price: 0.090 pence each, up 5.9% on early Monday afternoon in London 12-month change: down 50% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
